Management Software
Fri, July 30, 2010
| | |
 | |
 | |
 |
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo IR for Moderate to Severe Acute Pain
efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete dosing by close of Q2 2010.
Stay Updated Now!Responses are currently closed, but you can trackback from your own site.
|